NCT06961435View on ClinicalTrials.gov

An Analysis of the Relationship Between the Genetic Polymorphisms of Plasminogen Activator Inhibitor-1 and Ulcerative Colitis in Chinese Patients

CompletedOBSERVATIONAL

Enrollment

900

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions

Colitis, Ulcerative

Interventions

BIOLOGICAL

Vedolizumab

Intravenous injection of VDZ (300mg/time) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of VDZ every 8 weeks to maintain treatment.

Trial Locations (1)

325000

the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors

lead

Second Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06961435 - An Analysis of the Relationship Between the Genetic Polymorphisms of Plasminogen Activator Inhibitor-1 and Ulcerative Colitis in Chinese Patients | Biotech Hunter | Biotech Hunter